ArticlePloS one2009
Discovery of novel serum biomarkers for prenatal Down syndrome screening by integrative data mining.
Article in PloS one, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Application of intelligent algorithms in Down syndrome screening during second trimester pregnancy.World journal of clinical cases · 2021Article
- Review
- PolySearch2: a significantly improved text-mining system for discovering associations between human diseases, genes, drugs, metabolites, toxins and more.Nucleic acids research · 2015Article
- Predictive performance of a seven-plex antibody array in prenatal screening for Down Syndrome.Disease markers · 2015Article
- The developmental basis of epigenetic regulation of HTR2A and psychiatric outcomes.Journal of cellular biochemistry · 2014Review
- Maternal plasma and amniotic fluid chemokines screening in fetal Down syndrome.Mediators of inflammation · 2014Article
- Mining biomarker information in biomedical literature.BMC medical informatics and decision making · 2012Article
- Bioinformatics characterization of differential proteins in serum of mothers carrying Down syndrome fetuses: combining bioinformatics and ELISA.Archives of medical science : AMS · 2012Article
- 2D DIGE analysis of maternal plasma for potential biomarkers of Down Syndrome.Proteome science · 2011Article
- Article
- Biomarker discovery for Alzheimer's disease, frontotemporal lobar degeneration, and Parkinson's disease.Acta neuropathologica · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo facilitate the experimental search for novel maternal serum biomarkers in prenatal Down Syndrome screening, we aimed to create a set of candidate biomarkers using a data mining approach. METHODOLOGY/PRINCIPAL
findingsBecause current screening markers are derived from either fetal liver or placental trophoblasts, we reasoned that new biomarkers can primarily be found to be derived from these two tissues. By applying a three-stage filtering strategy on publicly available data from different sources, we identified 49 potential blood-detectable protein biomarkers. Our set contains three biomarkers that are currently widely used in either first- or second-trimester screening (AFP, PAPP-A and fbeta-hCG), as well as ten other proteins that are or have been examined as prenatal serum markers. This supports the effectiveness of our strategy and indicates the set contains other markers potentially applicable for screening. CONCLUSIONS/SIGNIFICANCE: We anticipate the set will help support further experimental studies for the identification of new Down Syndrome screening markers in maternal blood.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.